EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Tolvaptan safety in autosomal-dominant polycystic kidney disease; a focus on idiosyncratic drug-induced liver injury liabilities

Sean Hammond iD, Xiaoli Meng, Jane Barber, Merrie Mosedale iD, Amy Chadwick, Paul B Watkins iD, Dean J Naisbitt

Toxicological Sciences · 2025

DOI: 10.1093/toxsci/kfae142 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Toxicological Sciences, 2025. Verfasst von Sean Hammond und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Therapeutics, Centre for Drug Safety Science, University of Liverpool, Liverpool, L69 3GE, United Kingdom. Hauptthemen laut MEDLINE: Tolvaptan, Chemical and Drug Induced Liver Injury, Polycystic Kidney, Autosomal Dominant, Antidiuretic Hormone Receptor Antagonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tolvaptan is a vasopressin V2 receptor antagonist which has proven to be an effective and mostly well-tolerated agent for the treatment of autosomal-dominant polycystic kidney disease. However, its administration is associated with rare but serious idiosyncratic liver injury, which has warranted a black box warning on the drug labels and frequent monitoring of liver blood tests in the clinic. This review outlines mechanistic investigations that have been conducted to date and constructs a working narrative as an explanation for the idiosyncratic drug-induced liver injury (IDILI) events that have occurred thus far. Potential risk factors which may contribute to individual susceptibility to DILI reactions are addressed, and key areas for future investigative/clinical development are highlighted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TolvaptanChemical and Drug Induced Liver InjuryPolycystic Kidney, Autosomal DominantAntidiuretic Hormone Receptor AntagonistsHumansAnimalsRisk Factors

Stichwörter der Autor:innen

ADPKDT-celldrug induced liver injuryhypersensitivityidiosyncratictolvaptan

Substanzen

TolvaptanAntidiuretic Hormone Receptor Antagonists

Autor:innen und Institutionen

  • Department of Pharmacology and Therapeutics, Centre for Drug Safety Science, University of Liverpool, Liverpool, L69 3GE, United Kingdom.
  • ApconiX, Alderley Edge, SK10 4TG, United Kingdom.
  • Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, NC 27599, United States.

ORCID-Profile: Sean Hammond, Merrie Mosedale, Paul B Watkins

Zitieren

APA

Hammond, S., Meng, X., Barber, J., Mosedale, M., Chadwick, A., Watkins, P. B., & Naisbitt, D. J. (2025). Tolvaptan safety in autosomal-dominant polycystic kidney disease; a focus on idiosyncratic drug-induced liver injury liabilities. Toxicological Sciences. https://doi.org/10.1093/toxsci/kfae142

Vancouver

Hammond S, Meng X, Barber J, Mosedale M, Chadwick A, Watkins PB, et al. Tolvaptan safety in autosomal-dominant polycystic kidney disease; a focus on idiosyncratic drug-induced liver injury liabilities. Toxicological Sciences. 2025. doi:10.1093/toxsci/kfae142

BibTeX
@article{Hammond2025,
  author = {Hammond, Sean and Meng, Xiaoli and Barber, Jane and Mosedale, Merrie and Chadwick, Amy and Watkins, Paul B and Naisbitt, Dean J},
  title = {Tolvaptan safety in autosomal-dominant polycystic kidney disease; a focus on idiosyncratic drug-induced liver injury liabilities},
  journal = {Toxicological Sciences},
  year = {2025},
  doi = {10.1093/toxsci/kfae142}
}
Kostenlos starten →